Author:
Ilie M.,Long-Mira E.,Bence C.,Butori C.,Lassalle S.,Bouhlel L.,Fazzalari L.,Zahaf K.,Lalvée S.,Washetine K.,Mouroux J.,Vénissac N.,Poudenx M.,Otto J.,Sabourin J.C.,Marquette C.H.,Hofman V.,Hofman P.
Funder
Fondation ARC pour la recherche sur le cancer
Boehringer-Ingelheim
France
Reference22 articles.
1. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014
2. Immune checkpoint modulation for non-small cell lung cancer;Soria;Clin Cancer Res,2015
3. Refining the treatment of NSCLC according to histological and molecular subtypes;Thomas;Nat Rev Clin Oncol,2015
4. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study;Horn;J Clin Oncol,2015
5. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR);Spira;J Clin Oncol,2015
Cited by
483 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献